Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 3 , Pages 593-601 , March 2009

Sinus Tracts—An Early Sign of Bisphosphonate-Associated Osteonecrosis of the Jaws?

  • Hani Mawardi, BDS

      Affiliations

    • Graduate Student, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Mawardi: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115
    • ,
  • Nathaniel Treister, DMD, DMSc

      Affiliations

    • Instructor, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA; Attending, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA
    • ,
  • Paul Richardson, MD

      Affiliations

    • LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
    • ,
  • Kenneth Anderson, MD

      Affiliations

    • LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
    • ,
  • Nikhil Munshi, MD

      Affiliations

    • LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
    • ,
  • Robert A. Faiella, DMD, MMSc

      Affiliations

    • Periodontist, Private Practice, Osterville, MA
    • ,
  • Sook-Bin Woo, DMD, MMSc

      Affiliations

    • Assistant Professor, Department of Oral Medicine and Oral Pathology, Harvard School of Dental Medicine, Boston, MA; Attending, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA

References 

  1. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest. 1996;97:2692
  2. Russell RG. Bisphosphonates: Mode of action and pharmacology. Pediatrics. 2007;119(suppl 2):S150
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  4. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  6. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007. 2007;65:369
  7. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479
  8. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464
  9. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082
  10. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (Myeloma Aredia Study Group). N Engl J Med. 1996;334:488
  11. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  12. Jadu F, Lee L, Pharoah M, et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18:2015
  13. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328
  14. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?. J Oral Maxillofac Surg. 2006;64:917
  15. Lexi-Comp. Alendronate: Drug information. Whitehouse Station, NJ: Merck & Co; 2008;
  16. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  17. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  18. Calhoun KH, Shapiro RD, Stiernberg CM, et al. Osteomyelitis of the mandible. Arch Otolaryngol Head Neck Surg. 1988;114:1157
  19. Neville BW, Damm DD, Allen CM, et al. Osteomyelitis, in Oral and Maxillofacial Pathology. In: (ed 2). Philadelphia: Saunders; 2002;p. 126
  20. D'Silva NJ, Summerlin DJ, Cordell KG, et al. Metastatic tumors in the jaws: A retrospective study of 114 cases. J Am Dent Assoc. 2006;137:1667
  21. Zachariades N. Neoplasms metastatic to the mouth, jaws and surrounding tissues. J Craniomaxillofac Surg. 1989;17:283
  22. Bedogni A, Saia G, Ragazzo M, et al. Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone. 2007;41:942
  23. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician. 2006;35:801
  24. McMahon RE, Bouquot JE, Glueck CJ, et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg. 2007;65:1899
  25. Arlet J, Ficat P. Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage). Rev Chir Orthop Reparatrice Appar Mot. 1968;54:637
  26. Ficat P, Arlet J. Pre-radiologic stage of femur head osteonecrosis: Diagnostic and therapeutic possibilities. Rev Chir Orthop Reparatrice Appar Mot. 1973;59(suppl 1):26
  27. Jones LC, Hungerford DS. Osteonecrosis: Etiology, diagnosis, and treatment. Curr Opin Rheumatol. 2004;16:443
  28. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567
  29. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99
  30. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: Another clinical variant?. J Oral Maxillofac Surg. 2008;66:1516

PII: S0278-2391(08)01515-2

doi: 10.1016/j.joms.2008.09.031

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 3 , Pages 593-601 , March 2009

Article Tools

* Image Usage & Resolution